1.
Alvarez MJ, Subramaniam PS, Tang LH, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018;50(7):979-989. doi:10.1038/s41588-018-0138-4.
1.
Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45(12):1483-6. doi:10.1038/ng.2821.
1.
Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun. 2015;6:6517. doi:10.1038/ncomms7517.
1.
Gould KA, Dietrich WF, Borenstein N, Lander ES, Dove WF. Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice. Genetics. 1996;144(4):1769-76.
1.
Gould KA, Luongo C, Moser AR, et al. Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics. 1996;144(4):1777-85.
1.
Luongo C, Gould KA, Su LK, et al. Mapping of multiple intestinal neoplasia (Min) to proximal chromosome 18 of the mouse. Genomics. 1993;15(1):3-8. doi:10.1006/geno.1993.1002.
1.
Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet. 1997;17(1):88-91. doi:10.1038/ng0997-88.
1.
Dietrich WF, Radany EH, Smith JS, Bishop JM, Hanahan D, Lander ES. Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc Natl Acad Sci U S A. 1994;91(20):9451-5.
1.
Fazeli A, Steen RG, Dickinson SL, et al. Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc Natl Acad Sci U S A. 1997;94(19):10199-204.